161 related articles for article (PubMed ID: 15604890)
21. Fatal hyperacute graft-versus-host disease following denileukin diftitox treatment for recurrent t cell lymphoma after allogeneic stem cell transplantation.
Khubchandani S; Deeb G; Smiley SL; Battiwalla M; Paplham P; Brown K; Syta M; Hahn T; Cheney R; McCarthy PL; Hong F
Biol Blood Marrow Transplant; 2009 Jul; 15(7):887-90. PubMed ID: 19539223
[No Abstract] [Full Text] [Related]
22. The role of the extracorporeal photopheresis in the management of the graft-versus-host disease.
Kaloyannidis P; Mallouri D
Transfus Apher Sci; 2012 Apr; 46(2):211-9. PubMed ID: 22123355
[TBL] [Abstract][Full Text] [Related]
23. Extracorporeal photopheresis performed on the CELLEX® compared with the UVAR-XTS® instrument is more efficient and better tolerated in children with steroid-refractory graft-versus-host disease.
Kapadia E; Wong E; Perez-Albuerne E; Jacobsohn D
Pediatr Blood Cancer; 2015 Aug; 62(8):1485-8. PubMed ID: 25881179
[TBL] [Abstract][Full Text] [Related]
24. Management of graft-versus-host disease.
Arai S; Vogelsang GB
Blood Rev; 2000 Dec; 14(4):190-204. PubMed ID: 11124107
[TBL] [Abstract][Full Text] [Related]
25. Current and novel therapies in acute GVHD.
Ho VT; Cutler C
Best Pract Res Clin Haematol; 2008 Jun; 21(2):223-37. PubMed ID: 18503988
[TBL] [Abstract][Full Text] [Related]
26. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.
Alam N; Atenafu EG; Tse G; Viswabandya A; Gupta V; Kim D; Lipton JH; Messner HA; Kuruvilla J
Clin Transplant; 2013; 27(6):930-7. PubMed ID: 24304375
[TBL] [Abstract][Full Text] [Related]
27. Steroid-refractory graft-vs.-host disease: past, present and future.
Carpenter PA; Sanders JE
Pediatr Transplant; 2003; 7 Suppl 3():19-31. PubMed ID: 12603689
[TBL] [Abstract][Full Text] [Related]
28. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
Srinivasan R; Chakrabarti S; Walsh T; Igarashi T; Takahashi Y; Kleiner D; Donohue T; Shalabi R; Carvallo C; Barrett AJ; Geller N; Childs R
Br J Haematol; 2004 Mar; 124(6):777-86. PubMed ID: 15009066
[TBL] [Abstract][Full Text] [Related]
29. Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.
Schroeder T; Haas R; Kobbe G
Expert Rev Hematol; 2010 Oct; 3(5):633-51. PubMed ID: 21083479
[TBL] [Abstract][Full Text] [Related]
30. Denileukin diftitox: a concise clinical review.
Eklund JW; Kuzel TM
Expert Rev Anticancer Ther; 2005 Feb; 5(1):33-8. PubMed ID: 15757436
[TBL] [Abstract][Full Text] [Related]
31. Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model.
Knueppel A; Lange S; Altmann S; Sekora A; Knuebel G; Vogel H; Lindner I; Freund M; Junghanss C
Vet Immunol Immunopathol; 2012 Jan; 145(1-2):233-40. PubMed ID: 22173275
[TBL] [Abstract][Full Text] [Related]
32. Graft-versus-host disease after allogeneic stem cell transplantation: evolving concepts and novel therapies including photopheresis.
Komanduri KV; Couriel D; Champlin RE
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):1-6. PubMed ID: 16399595
[TBL] [Abstract][Full Text] [Related]
33. [Extracorporeal photopheresis in the treatment of patients with refractory chronic graft-versus-host disease after allogeneic bone marrow transplantation].
Bykova TA; Kozlov AV; Stancheva NV; Semënova EV; Kulagina II; Bondarenko SN; Vavilov VN; Morozova EV; Zubarovskaia LS; Afanas'ev BV
Ter Arkh; 2013; 85(8):60-8. PubMed ID: 24137966
[TBL] [Abstract][Full Text] [Related]
34. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus.
Mookerjee B; Altomonte V; Vogelsang G
Bone Marrow Transplant; 1999 Sep; 24(5):517-20. PubMed ID: 10482936
[TBL] [Abstract][Full Text] [Related]
35. Revisiting mycophenolate mofetil for steroid-refractory acute graft-versus-host disease: Is higher dosing effective in children?
Levine JE
Pediatr Transplant; 2015 Sep; 19(6):582-3. PubMed ID: 26215797
[No Abstract] [Full Text] [Related]
36. Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease.
Wolff D; Steiner B; Hildebrandt G; Edinger M; Holler E
Curr Pharm Des; 2009; 15(17):1974-97. PubMed ID: 19519437
[TBL] [Abstract][Full Text] [Related]
37. Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients.
Weitz M; Strahm B; Meerpohl JJ; Bassler D
Cochrane Database Syst Rev; 2014 Feb; (2):CD009898. PubMed ID: 24569961
[TBL] [Abstract][Full Text] [Related]
38. C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation.
Minculescu L; Kornblit BT; Friis LS; Schiødt I; Petersen SL; Andersen NS; Sengeloev H
Biol Blood Marrow Transplant; 2018 Mar; 24(3):600-607. PubMed ID: 29074374
[TBL] [Abstract][Full Text] [Related]
39. T cell costimulation blockade for hyperacute steroid refractory graft versus-host disease in children undergoing haploidentical transplantation.
Jaiswal SR; Zaman S; Chakrabarti A; Sehrawat A; Bansal S; Gupta M; Chakrabarti S
Transpl Immunol; 2016 Nov; 39():46-51. PubMed ID: 27577170
[TBL] [Abstract][Full Text] [Related]
40. Extracorporeal photopheresis in acute and chronic graft-versus-host disease.
Greinix HT; Worel N; Just U; Knobler R
Transfus Apher Sci; 2014 Jun; 50(3):349-57. PubMed ID: 24780392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
